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Abstract: Escherichia coli is the most frequent Gram-negative bacilli involved in intra-abdominal
infections. However, despite high mortality rates associated with biliary tract infections due to E. coli,
there is no study focusing on this pathogen. In this study, we have characterized a group of 15 E. coli
isolates obtained from 12 patients with biliary tract infections. Demographic and clinical data of
the patients were recovered. Phylogeny, resistome, and virulome analysis through whole genome
sequencing and biofilm formation were investigated. Among the 15 E. coli isolates, no predominant
sequence type (ST) was identified, although 3 of them belonged to unknown STs (20%). Resistance
to ampicillin, amoxicillin/clavulanic acid, cotrimoxazole, and quinolones was more present in these
isolates; whereas, third and fourth generation cephalosporins, carbapenems, amikacin, tigecycline,
and colistin were highly active. Moreover, high diversity of virulence factors has been found, with sfa,
fimH, and gad the most frequently detected genes. Interestingly, 26.6% of the E. coli isolates were high
biofilm-producers. Altogether, our data characterized for the first time E. coli isolates associated with
biliary tract infections in terms of genomic relationship, resistome, and virulome.
Keywords: Escherichia coli; biliary tract infection; virulome; resistome; biofilm
1. Introduction
Escherichia coli is a Gram-negative bacterium with high clinical relevance. This microorganism
may cause severe community- and hospital-acquired infections including bacteraemia, urinary tract,
respiratory, and intra-abdominal infections [1]. Among intra-abdominal infections, acute cholangitis,
an infection of the biliary system, is usually associated with high morbidity and mortality (5–13%) [2,3],
reaching up to 29% in cases of malignant obstruction [3]. In case of biliary tract infection, E. coli was
reported to be the most frequent pathogen isolated from bile samples (23%) [4].
E. coli sequence type 131 (ST131) identified by multilocus sequence typing (MLST) has been
reported as the most prevalent clonal group worldwide, frequently associated with multidrug-resistance
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(MDR) and infections [5]. Other pandemic lineages such as ST69, ST95, and ST73 have been also
associated with more virulent E. coli isolates [6,7]. Focusing at the abdominal level, the phylogenetic
group B2 of E. coli non ST131 has been described in inflammatory bowel disease [8]. However, the
epidemiology of E. coli causing biliary tract infection is poorly documented.
E. coli needs to move from the large intestine to the biliary tract to produce a biliary tract infection.
This process depends on virulence factors that are usually located in pathogenicity islands and can be
divided into five main groups: 1) adhesins, 2) toxins, 3) siderophores, 4) capsular, and 5) protectins
and invasins [9]. Thus, some genes coding for virulence factors have been associated with urinary tract
infections and bacteraemia such as pap, fimH, sfa, iha, bfp (adhesins), hlyA, cnf1, sat (toxins), fyuA, iutA
(siderophores), kpsMTII (capsule) and aer, traT, ompT, usp, and malX (miscellaneous proteins) [10–14].
However, to our knowledge, only limited studies investigated the microbiological features of E. coli
causing biliary tract infections [15,16], despite the fact that E. coli is the most frequent etiological
agent [17]. Characterizing the virulence factors that facilitate the establishment of biliary tract infections
in E. coli may be helpful in order to identify potential targets that could be locked as a therapeutic
strategy. To this end, we examined the clonal relationship, the resistome, and virulome in 15 E. coli
isolates responsible for biliary tract infections in Spain.
2. Materials and Methods
2.1. Bacterial Strains
Fifteen E. coli isolates obtained from bile and blood of 12 patients with biliary tract infection (BTI),
and 21 isolates of 20 patients with non-BTI (bacteremia and non-biliary intraabdominal infections)
hospitalized at the University Hospital Virgen del Rocío (Seville, Spain) were included in this study.
The isolates were collected at the Clinical Microbiology Service from blood and/or bile samples of
these patients and then, stored at −80 ◦C in Luria Bertani (LB) broth supplemented with 30% glycerol.
Identification of the isolates was performed using MALDI-TOF (Bruker Daltonik GmbH, Leipzig,
Germany), as described previously [18] and whole genome sequencing (WGS) (HiSeq systems, Illumina,
USA). E. coli ATCC 10536 strain was used as the positive control for biofilm formation. E. coli ATCC
25922 was used as the control strain for antibiotic susceptibility testing.
2.2. Demographics, Clinical Data, and Follow Up
The diagnosis of the biliary tract infection was made by members of the Infectious Disease
Service and/or the Intensive Care Unit (ICU), according to the defined criteria [19]. The following
variables were collected from the 12 BTI and 20 non-BTI patients: age and gender, Charlson score,
an index that categorize comorbidity of patients based on the International Classification of Diseases
diagnosis code [20] and McCabe score, a score that can obtain comparisons regarding the importance
of host factors based on the severity of the underlying disease [21], the acquisition type of the BTI
and non-BTI (community, healthcare-associated, or hospital), severity (sepsis or septic shock) [22],
antibiotic exposure in the previous 2 months of hospitalization and duration of the antimicrobial
treatment. The patients were followed until hospital discharge, death, or 30 days, which ever occurred
first. The study was approved by the Ethics Committee of the University Hospital Virgen del Rocío
and University Hospital of Virgen Macarena of Seville (approval no. 0023-N-16, 01/10/2016). Written
informed consent was signed by all patients before inclusion in the study.
2.3. Antimicrobial Resistant Profile
The minimum inhibitory concentration (MIC) was determined by broth microdilution method
using MicroScan Walk Away NM44 panels (Beckman Coulter, Inc., USA) for the following antibiotics:
ampicillin, amoxicillin-clavulanic acid, piperacillin-tazobactam, cefuroxime, cefotaxime, ceftazidime,
cefepime, imipenem, meropenem, ciprofloxacin, levofloxacin, gentamicin, tobramycin, amikacin,
cotrimoxazole, and tigecycline. Colistin was tested by standard broth microdilution as recommended by
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the European Committee of Antimicrobial Susceptibility Testing (EUCAST) [23] and the interpretation
criteria was performed following the EUCAST breakpoints [24]. MDR criteria were established as
non-susceptible to ≥1 agent in ≥3 antimicrobial categories [25]. E. coli ATCC 25922 was used as the
control strain.
2.4. Whole Genome Sequencing
Genomic DNA was extracted using an UltraClean microbial DNA isolation kit (MO BIO
Laboratories, Mo-Bio, Sait-Quentin en Yvelines, France) from overnight cultures in LB agar (Bio-Rad,
Marnes-la-Coquette, France). Genomic DNA quantification was performed using a Qubit fluorometer
(Life Technologies, Carlsbad, CA, USA) and adjusted to 0.2 ng/µL. The DNA libraries were prepared
using the NexteraXT v3 kit (Illumina, San Diego, CA, USA), according to the manufacturer’s
instructions, and then run on the HiSeq systems (Illumina, USA) to generate paired-end 150-bp
reads. De novo assembly of Illumina reads was performed using CLC genomic workbench 10.1
according the manufacturer’s recommendations (Qiagen, Courtaboeuf, France). The genome was
annotated using the Rapid Annotations using Subsystems Technology (RAST) tool. The acquired
antimicrobial resistance genes were identified by uploading assembled genomes to the Resfinder
server v2.1 (http://cge.cbs.dtu.dk/services/ResFinder-2.1) [26]. Virulence genes were searched using
https://cge.cbs.dtu.dk/services/VirulenceFinder/.
2.5. Phylogenetic Analysis
Sequence alignment and phylogenetic trees were performed using the software MEGA7 and
Evolview online tool [27,28]. Neighbor-joining trees were built from concatenated sequences of the 7
housekeeping genes (adk, fumC, gyrB, icd, mdh, purA, and recA) used previously in MLST assay [29],
and obtained for whole genome sequencing analysis. The evolutionary distances were computed
using Kimura’s two-parameter model with gamma-distributed rate variation of 0.8 [30]. A bootstrap
consensus tree inferred from 1000 replicates was depicted to represent the evolutionary history of the
taxa analyzed [31].
2.6. Biofilm Formation Assay
An abiotic solid surface biofilm formation assay was performed as described previously [32].
In brief, overnight cultures of the clinical E. coli isolates were diluted 1:100 in fresh LB broth in 96 well
plates without shaking and incubated at 37 ◦C for 48 h. Biofilm was stained with crystal violet 0.4%
(v/v) and quantified at 580 nm after solubilization with ethanol 95%. E. coli isolates were classified as
biofilm-formers if they yielded optical density at 580 nm (OD580nm) values that were at least twice
those of the negative control. E. coli ATCC 10536 strain was used as positive control.
2.7. Statistical Analysis
A descriptive analysis was performed for demographics and clinical variables of the patients
included in the study, with median and interquartile range for the quantitative variables and frequency
distribution (%) for the qualitative variables. Fisher and χ2 tests were used for categorical variables
and continuous variables were analyzed using 2-sample t test or Mann Whitney U test. For biofilm
formation assay, the group data are presented as mean ± SEM. Differences were considered significant
at p < 0.05. All statistical analyses were performed using SPSS software, version 23.0 (IBM Corporation,
Somers, New York, USA).
2.8. Nucleotide Sequence Accession Number
The WGS of the E. coli isolates generated in the study were deposited in GenBank under the
BioProject accession number PRJNA557044.
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3. Results
3.1. Bacterial Isolates
MALDI-TOF identified the 15 bacterial isolates from the 12 patients with bile infections, following
the clinical criteria established by Solomkin et al. [19], as E. coli. Among them, 11 (73.3%) were isolated
from bile samples and 4 (26.6%) from blood cultures. Three patients had two isolates each: 140-HE and
23-AE from blood and bile cultures, 43-HE and 4-AE from blood and bile cultures, and 60-AE and
61-AE from the bile culture, respectively.
3.2. Demographics and Clinical Data Analysis
Demographic and clinical features of the 12 and 20 patients with biliary tract infections (BTI) and
non-BTI, respectively, included in this study are detailed in Table 1. To summarize, for both group of
patients, the demographic (age and gender), comorbidities (Charlson and McCabe scores), sepsis or
septic shock, and previous treatment and days of treatment were not significantly different. Regarding
to the acquisition of the infection, significant difference was observed between both groups (p = 0.035).
Importantly, there was no difference in mortality between both groups.
Table 1. Demographics and clinical data from patients with biliary tract infections (BTI) and non-BTI
by E. coli.
Variable BTI Patients(n = 12) Non-BTI Patients (n = 20) P-Value
Age, median (range) 64 (58–72.5) 64.5 (55.75–77.75) 0.893
Gender (female), n (%) 7 (58.3) 10 (50.0) 0.647
Charlson Score, median (range) 1.5 (0–3.75) 3 (0.25–6) 0.146
McCabe Score ultimately or rapidly fatal, n (%) 2 (16.6) 11 (55.0) 0.062
Acquisition, n (%)
Community 9 (75.0) 6 (30.0)
0.035Healthcare 2 (16.6) 5 (25.0)
Nosocomial 1 (8.3) 9 (45.0)
Sepsis or septic shock, n (%) 3 (25.0) 10 (50.0) 0.267
Previous antibiotic exposure, n (%) 7 (58.3) 13 (65.0) 0.724
Days of treatment, median (range) 12.5 (5–21) 10 (8–13) 0.329
Death, n (%) 3 (25.0) 3 (15.0) 0.647
BTI, biliary tract infection.
3.3. Antimicrobial Resistance Profile
Antimicrobial susceptibility testing results are shown in Table 2. Non-significant difference has
been observed between BTI and non-BTI isolates. The most frequent resistance found in BTI isolates
was by far Ampicillin (73.3%), followed by amoxicillin-clavulanic acid (26.6%), cotrimoxazole (26.6%),
and fluoroquinolones (13.3%). The rest of the antibiotics (third and fourth generation cephalosporins,
carbapenems, amikacin, tigecycline, and colistin) were highly active against these E. coli isolates.
For the non-BTI isolates, the most frequent resistance was by far Ampicillin (90.4%), followed by
fluorquinolones (33.33%), amoxicillin-clavulanic acid (28.6%), cotrimoxazole (28.5%), and cefuroxime
(14.3%). The rest of the antibiotics were highly active.
A MDR (resistance to beta-lactams including or not cephalosporins, beta-lactams/beta-lactamases
inhibitors, fluoroquinolones, cotrimoxazole, and/or aminoglycoside) pattern was found in 2 and 5 BTI
and non-BTI isolates (13.3% and 23.8%), respectively. Extended spectrum beta-lactamase (ESBL) was
only detected in the 2 non-BTI isolates; whereas, carbapenemase production were not detected in any
of the BTI and non-BTI isolates.
J. Clin. Med. 2019, 8, 2118 5 of 12
Table 2. Antimicrobial resistance in E. coli isolates causing BTI and non-BTI.
BTI E. coli (n = 15) Non-BTI E. coli (n = 21) P-Value
Ampicillin, n (%) 11 (73.3) 19 (90.4) 0.210
Amoxicillin-clavulanic acid, n (%) 4 (26.6) 6 (28.6) 1.000
Piperacillin-tazobactam, n (%) 2 (13.3) 1 (4.7) 0.559
Cefuroxime, n (%) 1 (6.6) 3 (14.3) 0.626
Cefotaxime, n (%) 0 (0.0) 2 (9.5) 0.500
Ceftazidime, n (%) 0 (0.0) 2 (9.5) 0.500
Cefepime, n (%) 0 (0.0) 2 (9.5) 0.500
Imipenem, n (%) 0 (0.0) 0 (0.0) 1.000
Meropenem, n (%) 0 (0.0) 0 (0.0) 1.000
Ciprofloxacin, n (%) 2 (13.3) 7 (33.3) 0.252
Levofloxacin, n (%) 2 (13.3) 7 (33.3) 0.252
Gentamicin, n (%) 1 (6.6) 2 (9.5) 1.000
Tobramycin, n (%) 1 (6.6) 2 (9.5) 1.000
Amikacin, n (%) 0 (0.0) 0 (0.0) 1.000
Cotrimoxazole, n (%) 4 (26.6) 6 (28.5) 1.000
Tigecycline, n (%) 0 (0.0) 0 (0.0) 1.000
Colistin, n (%) 0 (0.0) 0 (0.0) 1.000
ESBL, n (%) 0 (0.0) 2 (9.5) 0.500
MDR, n (%) 2 (13.3) 5 (23.8) 0.674
BTI, biliary tract infection; ESBL, extended spectrum beta-lactamase; MDR, multidrug-resistant.
3.4. Genetic Characterization
3.4.1. Epidemiology
The WGS analysis of the E. coli isolates showed that 12 isolates belonged to 10 different STs
and 3 isolates (3-AE, 47-HE, and 61-AE) belonged to novel STs (Table 3). Moreover, the isolate pairs
recovered from the same patient 140-HE and 23-AE, and 43-HE and 4-AE belonged to ST131 and ST58,
respectively. In contrast, the isolate pair 60-AE and 61-AE corresponded to two different STs, namely
ST542 and an unknown ST, respectively.
Table 3. Typing of 15 E. coli isolates by multilocus sequence typing.
Strain Source adk fumC gyrB icd mdh purA recA ST ST Complex
1-HE Blood 6 346 12 1 20 13 7 2230 23
43-HE ˆ Blood 6 4 4 16 24 8 14 58 155
47-HE Blood 6 95 15 18 9 8 6 Unknown -
140-HE * Blood 53 40 47 13 36 28 29 131 131
23-AE * bile 53 40 47 13 36 28 29 131 131
3-AE Bile 13 6 15 13 16 10 122 Unknown -
4-AE ˆ Bile 6 4 4 16 24 8 14 58 155
8-AE Bile 6 23 3 16 9 8 6 3640 -
16-AE Bile 10 11 4 8 8 8 2 10 10
24-AE Bile 13 13 9 13 16 10 9 12 12
60-AE ~ Bile 112 11 5 12 8 8 86 542 -
61-AE ~ Bile 112 40 4 12 8 8 86 Unknown -
66-AE Bile 21 35 27 6 5 5 4 69 69
81-AE Bile 13 52 10 14 17 25 17 141 -
82-AE Bile 6 4 14 16 24 8 14 155 155
ˆ,* E. coli isolated from blood and bile samples of the same patient. ~ E. coli isolated from bile of the same patient. ST:
sequence type.
The phylogenetic analysis of the concatenated sequences of the seven MLST housekeeping genes
of each isolate showed a tree consisting of three clusters and one branch formed by only one isolate that
belonged to ST69 (66-AE) and unrelated phylogenetically to the other isolates. The cluster 1 contained
5 isolates; two of them (140-HE and 23-AE) belonged to ST131 and 1 (3-AE) to an unknown ST related
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to ST12 complex. The cluster 2 contained 3 isolates; one of them (61-AE) belonged to an unknown ST
related to ST542. Finally, the cluster 3 had 6 isolates; one of them (47-HE) belonged to an unknown ST
related to ST3640 (Figure 1).
Figure 1. Phylogenetic tree using neighbor-joining method with 1000 bootstrap replicas of the 15 E. coli
isolates from the patients with biliary tract infections.
3.4.2. Virulome
The WGS analysis has identified several genes coding for virulence factors in the E. coli isolates
(Table 4). The most frequently detected genes were sfa (S fimbrial adhesin, 93.3%), fimH (type 1
Fimbriae, 93.3%), and gad (glutamate decarboxylase, 86.6%), followed by lpfA (long polar fimbria,
60.0%), iss (increased serum survival, 53.3%), iroN (enterobactin siderophore receptor protein, 53.3%),
iutA (ferric aerobactin receptor, 53.3%), mchF (ABC transporter protein, 46.6%), mchC (microcin
H47 maduration system, 20.0%), senB (enterotoxin, 20.0%), mchB (microcin H47, 13.3%), astA
(heat-stable enterotoxin-1, 13.3%), iha (irgA homologue adhesion, 13.3%), mcmA (microcin M, 13.3%), vat
(vacuolating autotransporter toxin, 13.3%), papG (P fimbrial adhesin, 13,3%), tsh (temperature-sensitive
hemagglutinin, 6.6%), air (enteroaggregative immunoglobulin repeat protein, 6.6%), eilA (Salmonella
hilA homologue, 6.6%), ireA (siderophore receptor, 6.6%), cnf1 (cytotoxic necrotizing factor-1, 6.6%),
and ipaH (invasion plasmid antigen, 6.6%). Other relevant virulence factors in E. coli such as hlyA
(hemolysin A), stx-1 and stx-2 (Shiga toxins-1 and -2), cdtB (cytolethal distending toxin), eaeA (intimin),
and bfp (bundle-forming pilus) were not found in these isolates.
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Table 4. Virulence genes from E. coli causing biliary tract infection.
Strain 1-HE 43-HE ˆ 47-HE 140-HE * 23-AE * 3-AE 4-AE ˆ 8-AE 16-AE 24-AE 60-AE ~ 61-AE ~ 66-AE 81-AE 82-AE
Source Blood Blood Blood Blood Bile Bile Bile Bile Bile Bile Bile Bile Bile Bile Bile
iss + + + + + + + +
ipfA + + + + + + + + +
mchC + + +
mchB + +
mchF + + + + + + +
iroN + + + + + + + +
tsh +
gad + + + + + + + + + + + + +
astA + + +
senB + + +
iha + +
air +
ailA +
mcmA + +
vat + +
ireA +
papG + +
sfa + + + + + + + + + + + + + +
fimH + + + + + + + + + + + + + +
iutA + + + + + + + +
ipaH +
cnf1 +
hlyA
cdtB
stx-1
stx-2
eaeA
bfp
Total 10 8 5 4 3 8 3 3 6 14 3 10 12 9 8
iss: increased serum survival, lpfA: long polar fimbria, mchC: microcin H47 maduration system, mchB: microcin
H47, mchF: ABC transporter protein, iroN: enterobactin siderophore receptor protein, tsh: temperature-sensitive
hemagglutinin, gad: glutamate decarboxylase, astA: heat-stable enterotoxin-1, senB: enterotoxin, iha: irgA homologue
adhesion, air: enteroaggregative immunoglobulin repeat protein, eilA: Salmonella hilA homologue, mcmA: microcin
M, vat: vacuolating autotransporter toxin, ireA: siderophore receptor, papG: P fimbrial adhesin, Sfa: S fimbrial
adhesin, fimH: type 1 Fimbriae, iutA: ferric aerobactin receptor, ipaH: invasion plasmid antigen, cnf1: 4cytotoxic
necrotizing factor-1, hlyA: hemolysin A, cdtB: cytolethal distending toxin, stx-1 and stx-2: Shiga toxins-1 and -2, eaeA:
intimin, and bfp: bundle-forming pilus. ˆ,* E. coli isolated from blood and bile samples of the same patient. ~ E. coli
isolated from bile of the same patient.
3.4.3. Resistome
The WGS revealed that the blaTEM-1a and blaTEM-1b genes, coding for the broad spectrum
beta-lactamase TEM-1, were the most frequently detected enzyme (66.6%). Mutations in gyrA,
parC, and parE genes, associated with fluoroquinolone resistance, were detected in 33%, 6.6%, and 20%
of the isolates, respectively. Resistance to aminoglycosides (aph, 40%; aadA, 33.3%; and strA, 13.3%),
sulphonamides (sul, 46.6%), trimethoprim (dfrA, 33.3%), tetracycline (tet, 20.0%), azithromycin (mph,
13.3%), and chloramphenicol (catA, 13.3%) were also detected in these isolates (Table 5).
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Table 5. Resistance genes from E. coli causing biliary tract infection.
Strain Source strA blaTEM catA sul tet dfrA aph gyrA parC parE aadA mph
1-HE Blood + 1a +
43-HE ˆ Blood 1b
47-HE Blood 1a + +
140-HE * Blood 1b + + +(I529L) + +
23-AE * Bile 1b + + +(I529L) + +
3-AE Bile + 1b + + + +
4-AE ˆ Bile +(S83L)
8-AE Bile
16-AE Bile 1b + +
24-AE Bile
60-AE ~ Bile 1b +(S83L)
61-AE ~ Bile + + + +(S83L) +(I529L) +
66-AE Bile 1b + + +
81-AE Bile
82-AE Bile 1b + + + + + +(S83L)(D87N) +(S80I) +
ˆ,* E. coli isolated from blood and bile samples of the same patient. ~ E. coli isolated from bile of the same patient. 1a
and 1b: two different blaTEM genes.
3.4.4. Biofilm Formation
The analysis of the biofilm formation in abiotic surface showed that 4 isolates (26.6%) were
biofilm-producers with OD580nm higher than 0.2. Two of them belonged to unknown ST (3-AE and
61-AE), one to ST2230 (1-HE), and one to ST542 (60-AE) (Figure 2).
Figure 2. Biofilm formation by the 15 E. coli isolates isolated from patients with biliary tract infection.
Unknown: unknown ST.
4. Discussion
This study shows, for the first time, the genomic relationship, resistome, and virulome of 15 E. coli
isolates obtained from bile and blood cultures of 12 patients with biliary tract infection. Twenty percent
of E. coli isolates belonged to unknown ST but with different allele combinations. This percentage is
higher than those found in other areas of infections such as urinary tract infection (3.5%), bloodstream
infection (10.5%), and left-sided inflammatory bowel disease (0%) [6,8,33]. Of note, twenty-one E. coli
isolates recovered from different non-biliary sources in our hospital and over the same period of
time were also characterized phylogenetically by MLST and none of them belonged to unknown STs
(Table S1).
Although, ST131, ST95, ST73, and ST69 are clearly predominant STs in human E. coli infections
such as urinary tract or bloodstream infections [7,34], in our study only 2 E. coli isolates (140-HE and
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23-AE, from the same patient) belonged to ST131 and another one (66-AE), to ST-69. The rest of the
isolates belonged to other STs, which suggests, even though the sample size of this study is small, that
in E. coli biliary tract infections, there is not a predominant ST. It is noteworthy to mention that 140-HE
and 23-AE isolates that belonged to ST131 had similar resistance profiles (resistance to ampicillin,
amoxicillin-clavulanic acid, and cotrimoxazole) with exception for piperacillin-tazobactam. Indeed,
the isolates 140-HE and 23-AE were categorized susceptible to piperacillin-tazobactam by MicroScan
and resistant to piperacillin-tazobactam by broth microdilution method. This could be due to the
presence of different heteroresistant populations that cannot be detected by the automated Microscan
system [35].
Regarding the antimicrobial resistance profiles of the 15 E. coli isolates of this study, ampicillin
showed the highest percentage of resistance (73.3%), followed by amoxicillin-clavulanic acid (26.6%),
cotrimoxazole (26.6%), and fluoroquinolones (13.3%). These data are in agreement with those of
WGS analysis (Table 5). Specifically, blaTEM genes involved in ampicillin resistance have been found
in 66.6% of the isolates, dfrA gene involved in trimethoprim resistance has been found in 33.3%
of the isolates, whereas gyrA and parE were more prevalent (33% and 20%) than the observed
fluoroquinolones resistance rate (13.3%). However, Razaghi et al. reported that 54%, 31.8%, 22.7%, and
0% of E. coli isolated from bile presented resistance to ciprofloxacin, meropenem, ceftazidime, and
amoxicillin-clavulanic acid, respectively [15]. These differences are likely the result of differences in
local epidemiology. In Spain, the analysis of a total of 1429 E. coli isolates causing intra-abdominal
infections in a surveillance study called SMART (Study for Monitoring Antimicrobial Resistance Trends)
between 2016 and 2017 revealed that ciprofloxacin and amoxicillin-clavulanic acid presented resistance
rates of 27.6% and 18.5%, respectively [36]. However, in Iran, the MDR pattern was detected in 95.5%
of the E. coli recovered from bile, reporting different antimicrobial resistance rates in comparison with
our results, mainly in the case of third generation cephalosporins (82% vs. 0%), carbapenems (≈70% vs.
0%), gentamicin (36.4% vs. 6.6%), and ciprofloxacin (45.5% vs. 13.3%), respectively [37].
The WGS showed a high diversity in the virulome among the E. coli isolates analyzed in this
study, similarly to Fernández-Romero et al. observations [38]. None of the virulence factors genes
detected were present in all of the isolates, indicating the absence of a unique gene essential for the
development of E. coli-borne biliary tract infections. However, three of the virulence factors were
detected in around 90% of the isolates: sfa and fimH that are involved in the adhesion to the cells and
facilitate the penetration of bacteria into the tissues [39], and gad, which expression is relevant for
the maintenance of E. coli in acid environments such as the biliary tract [40]. These data suggest that
adhesion ability and resistance to bile acids seem to be important to produce a biliary tract infection.
Transcriptomic confirmatory analyses will help to determine the involvement of these genes in the
infections development, especially in the patients with two isolates recovered from bile and blood,
respectively, in which the expression of these genes may change during the course of the infection.
Similar data have been reported by Wang et al. [16] who studied the role of virulence factors in the
development of E. coli bacteraemia in patients with acute cholangitis. They detected the presence of
fimH and iutA in 88% and 50% of the isolates, respectively; whereas, sfa was detected only in 8% of the
isolates [16]. Another study reported that bfp and astA were the most frequent virulence factors in E. coli
isolated from bile [15]; although they did not analyze the presence of fimH, sfa, or gad in their isolates.
It is important to mention, that no transcriptomic analyses were performed in this study to confirm the
degree of expression of these virulence genes, even though they might be or not be expressed.
Some genetic interconnections have been found between different isolates. It appears that the
isolate 3-AE could be the ancestor of the cluster 1. Some virulence genes (iss, ipfA, mchC, and mchB)
present in this isolate were lost when compared with the rest of the isolates of the cluster 1. In contrast,
other virulence genes (gad, mcmA, vat, and iutA) were acquired in the rest of the isolates of the cluster 1.
Similarly, we found that the isolate 60-AE acquired the genes iss, ipfA, iroN, astA, senB, iha, and iutA,
when compared with the isolate 61-AE recovered from the same patient. In the same line, the isolate
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47-HE, closely related to the isolate 8-AE, acquired the genes astA and fimH, when compared with the
isolate 8-AE.
Notably, we report, here, that the E. coli isolates do not only harbor virulence and resistance
genes, but also 26.6% of them were high biofilm-formers. However, the relationship between biofilm
formation and virulence or resistance pattern was not observed, and needs inclusion of more isolates
in the future.
5. Conclusions
This study characterized, for the first time by WGS, the molecular epidemiological traits, virulome,
and resistome of a collection of E. coli isolates from patients with biliary tract infections. Low proportion
of E. coli ST131 was found and most E. coli isolates belonged to different STs. Antimicrobial susceptibility
testing and WGS matched perfectly. Resistance to penicillins, cotrimoxazole, and fluoroquinolones
were the most frequently encountered resistances. Furthermore, a high diversity of virulence factors
was evidenced, with however, a predominance of genes involved in adhesion and resistance to biliary
acids. A better knowledge of the microbiological features of E. coli causing biliary tract infection is
important to improve the diagnosis and treatment of these patients.
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